Investor Relations

Investor Relations

Investor Menu

Corporate Overview

Developing transformative therapies targeting cancer

Seattle Genetics is a global, multi-product biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. We are commercializing ADCETRIS® for the treatment of several types of CD30-expressing lymphomas, PADCEV® for the treatment of locally advanced or metastatic urothelial cancer and TUKYSA™ for the treatment of certain HER2-positive metastatic breast cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS and PADCEV, are based on our proprietary antibody-drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

Recent News

View all news

Featured Presentation

View All Quarters